Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that NQO1 rs1800566 genetic polymorphism may contribute to bladder cancer development, especially in Asians.
|
23464456 |
2012 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of glutathione S-transferase (GST) enzymes (M1, T1), methylenetetrahydrofolate (MTHFR) 677 and 1298, and the NAD(P)H:quinone oxidoreductase (NQO1) polymorphisms in a population-based bladder cancer case-control study in Argentina.
|
15219943 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer.
|
23873104 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The highest odds for having bladder cancer following SH infection were observed among individuals with the CC genotypes for both NQO1 and SOD2 (OR [CI 95%] = 4.41 [2.32-8.38]).
|
24035474 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tissue from 148 patients with low to intermediate grade (G1/G2) superficial (Ta/T1) bladder cancers and NQO1*2 genotype status determined by PCR-RFLP.
|
15375541 |
2004 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Results of this study strongly suggest that the variant allele of NQO1 (Pro187Ser) may affect individual susceptibility to bladder cancer, particularly among smokers, in this ethnic Kashmiri population.
|
21253823 |
2011 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggests that NQO1 C609T polymorphism is associated with bladder cancer susceptibility.
|
23749485 |
2013 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Compared with study participants carrying the C/C genotype of NQO1 gene, those with C/T and T/T genotypes had a significantly increased BC risk of 1.8 (95% CI = 1.1-2.9).
|
24315573 |
2014 |
Malignant neoplasm of urinary bladder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The variant allele genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (odds ratio (OR)=1.51; 95% confidence interval (CI)=1.01-2.25).
|
12694753 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most notable findings are: GSTM1 deletion and bladder cancer risk [odds ratio (OR) = 1.60; 95% confidence interval 1.00-2.56]; CYP1A1 and leukemia (2.22, 1.33-3.70; heterozygotes); CYP1B1 and leukemia (0.47, 0.27-0.84; homozygotes); MnSOD and leukemia (1.91, 1.08-3.38; homozygotes) and NQO1 and lung cancer (8.03, 1.73-37.3; homozygotes).
|
17496311 |
2007 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a meta-analysis of the Exon 6 (C > T) polymorphism and BC risk showed that the variant of NQO1 Exon 6 genotypes was associated with an overall increased risk of BC, which was consistent with the results of the present study.
|
24676794 |
2014 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that the sensitivity of patient bladder tumors to MMC is correlated with the expression of DTD and P450R in tumors and suggest that the lower expression of these enzymes in the high-grade and more invasive tumors is a cause of the lower efficacy of intravesical MMC in these tumors.
|
11350900 |
2001 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of glutathione S-transferase (GST) enzymes (M1, T1), methylenetetrahydrofolate (MTHFR) 677 and 1298, and the NAD(P)H:quinone oxidoreductase (NQO1) polymorphisms in a population-based bladder cancer case-control study in Argentina.
|
15219943 |
2004 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The variant allele genotypes of NQO1 were associated with a higher risk of bladder cancer in Caucasians (odds ratio (OR)=1.51; 95% confidence interval (CI)=1.01-2.25).
|
12694753 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer.
|
23873104 |
2013 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Overall, the NQO1 187Ser carriers were associated with an increased bladder cancer risk (homozygous: OR = 1.43, 95% CI = 1.08-1.90; recessive: OR = 1.33, 95% CI = 1.03-1.72; dominant: OR = 1.19, 95% CI = 1.04-1.37, and allele comparing: OR = 1.18, 95% CI = 1.06-1.33).
|
25602258 |
2015 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our data are consistent with the notion that NQO1 polymorphisms influence the course and clinical outcomes of urinary bladder neoplasms.
|
17469025 |
2007 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings have suggested that the NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism combination with smoking significantly confer susceptibility to BC.
|
28589969 |
2017 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that CYP2E1 and NQO1 genotypes may play an important role in development of smoking related bladder cancer among Korean men.
|
12777965 |
2003 |